Assistant Manager
Projects & Process Engineering | 14 Years of Experience
A co-packaged combination product brings together two or more components, such as a drug and a device, in one pack but as separate items. They are not physically or chemically combined. First-aid kits, surgical kits, and a drug vial packed with an empty syringe are common examples. In the U.S., these products are regulated under 21 CFR 3.2(e) and 21 CFR Part 4, and the FDA’s Office of Combination Products decides jurisdiction based on the Primary Mode of Action (PMOA). In India, classification and licensing depend on whether CDSCO treats the product as drug-led or device-led under the Medical Device Rules, 2017.
Getting a co-packaged combination product to market means satisfying two regulatory systems at once, drug and device, often through a single submission. Most of these products stall in review for the same three reasons: misclassification, incomplete CGMP documentation, and unclear responsibility for labelling. This guide walks you through classification and compliance requirements, and shows how Operon Strategist helps manufacturers get it right the first time.
What Is a Co-Packaged Combination Product?
A co-packaged combination product contains two or more individual components, most often a drug and a device, packed together in a single unit without being chemically or physically combined. Because the components stay separate, classification depends on how they are meant to be used together, and not just on what is in the box.
Common examples include:
- An inhaler packed with a filled drug cartridge
- A drug delivered through a separate mechanism, such as a nebulizer, dropper, or syringe
- Convenience kits, such as first-aid kits or surgical kits
Regulatory expectations have grown well beyond simply pointing to an existing device registration, such as a 510(k). Reviewers now expect you to show that the drug and device work together as a system. That means covering functionality, compatibility, and human factors testing to confirm the combination delivers its intended clinical result.
Read Related Blog: Disposable Syringe Manufacturing Guide
Co-Packaged vs. Single-Entity vs. Cross-Labeled: What's the Difference?
FDA defines combination products under 21 CFR 3.2(e) in three configurations, and confusing them is one of the most common classification mistakes manufacturers make:
| Configuration | Definition | Example |
|---|---|---|
| Single-Entity | Components are physically or chemically combined into one product | Drug-eluting stent, prefilled syringe |
| Co-Packaged | Components are packaged together but remain separate items | Surgical kit with device + antiseptic drug |
| Cross-Labeled | Components are packaged separately but labeled for joint use | Light-activated drug labeled for use with a specific light-source device |
The 9 Types of Combination Products
| Type | Description | Common Examples |
|---|---|---|
| 1 | Convenience Kit or Co-Package | First-aid kits, surgical kits |
| 2 | Prefilled Drug Delivery Device/System | Prefilled syringes, auto-injectors, metered-dose inhalers, nasal sprays |
| 3 | Prefilled Biologic Delivery Device/System | Vaccine in a prefilled syringe or auto-injector |
| 4 | Device Coated/Impregnated/Combined with Drug | Drug-eluting stents, antimicrobial-coated catheters, spermicidal condoms, fluoride dental floss |
| 5 | Device Coated or Combined with Biologic | Cell-seeded device scaffolds, extracorporeal columns with bound protein |
| 6 | Drug/Biologic Combination | Antibody-drug conjugates |
| 7 | Separate Products Requiring Cross-Labeling | Light-activated drugs labeled for a specific light source |
| 8 | Possible Combination Based on Cross-Labeling | Drug/biologic in development where device pairing isn’t finalized |
| 9 | Other Part 3 Combination Product | Products combining all three constituent types, or overlapping combination types |
Manufacturers of co-packaged combination products with a device constituent part must establish and maintain CAPA procedures in accordance with 21 CFR 820.100.
How Are Co-Packaged Combination Products Classified? (FDA vs. CDSCO)
United States (21 CFR Part 3 & the FD&C Act)
- The FDA’s Office of Combination Products (OCP) oversees these products. It was set up to coordinate jurisdiction across CDER (drugs), CDRH (devices), and CBER (biologics).
- Classification rests on the Primary Mode of Action (PMOA). Whichever component provides the primary therapeutic effect decides which centre leads the review.
- If the PMOA is unclear, you can file a Request for Designation (RFD), and the FDA is generally required to respond within 60 days of filing. You can also seek informal feedback first through a Pre-RFD.
- You will need to show compliance with 21 CFR Part 4. It clarifies how drug CGMPs (21 CFR 210/211) and the device QSR/QMSR (21 CFR 820) apply to co-packaged and single-entity combination products. The approach is typically “streamlined”: one primary system, supplemented by specific requirements from the other.
India (CDSCO)
- These products fall under the Medical Device Rules, 2017 and the New Drugs and Clinical Trials Rules, 2019.
- CDSCO expects you to establish whether the product is drug-led or device-led, as this decides the licensing authority and the pathway.
- Getting the classification right at the start helps you avoid delays from filing under the wrong pathway.
Ensure FDA QSR Compliance for German Manufacturers with Expert Guidance
Testing & Documentation Requirements
Regulators expect testing that reflects how the product will actually be made and administered. That means using all the intended components and containment materials (vials, stoppers, syringes, and so on) and referring to recognised standards (ISO, USP, ASTM) wherever one exists. Where no standard directly applies, the testing should still cover every essential characteristic of how the drug is produced and delivered, using the closest applicable standard as a benchmark.
Because a co-packaged product has to be evaluated as a system and not as separate parts, you need documentation that ties everything together:
- Device Design History File (DHF) and device QSR/QMSR compliance
- Drug CGMP documentation under 21 CFR 210/211
- Human factors and usability testing that shows the drug and device work together as intended
- Combined or cross-referenced labelling and Instructions for Use (IFU)
Common Challenges in Co-Packaged Product Compliance
- Determining the Primary Mode of Action (PMOA), which is the single most common source of classification delay
- Harmonising drug and device documentation standards, since each constituent part usually comes with its own quality framework
- Usability engineering and human factors testing for the combination as a whole, and not just for the individual components
- Managing dual QMS compliance, meaning GMP (drugs) and ISO 13485 (devices), under one streamlined system
- Developing compliant labelling and IFUs that clearly explain how the components are meant to be used together
- Keeping submission timelines on track, without delays caused by incomplete or mismatched documentation between the drug and device sides
Why Choose Operon Strategist for Combination Product Compliance
✅ Global Regulatory Expertise: hands-on experience across the FDA, CDSCO, EU MDR, and other major markets
✅ Turnkey Solutions: support from PMOA and classification strategy right through to post-market
✅ Multidisciplinary Team: dedicated regulatory and quality affairs experts who understand both drug and device requirements
✅ Client-Centric Approach: regulatory pathways tailored to startups and established manufacturers alike
✅ Trusted Partner: 950+ successful projects across 32+ countries
We do not just consult. We work alongside you to take your co-packaged combination product from compliance to market.
Ensure FDA QSR Compliance for German Manufacturers with Expert Guidance
FAQ
What is a co-packaged combination product?
A co-packaged combination product contains two or more components — typically a drug and a device — packaged together as separate items, rather than physically or chemically combined. A surgical kit containing a device and an antiseptic drug is a common example.
What's the difference between co-packaged and single-entity combination products?
Single-entity products are physically or chemically combined into one item (such as a drug-eluting stent), while co-packaged products remain separate items packaged together (such as a drug vial packaged with an empty syringe).
Is a first-aid kit considered a combination product?
Yes. A first-aid kit combining a device (such as bandages) with a drug component (such as an antiseptic) is a common example of a co-packaged combination product.
How does the FDA classify combination products?
FDA classification is based on Primary Mode of Action (PMOA) — whichever constituent part provides the primary therapeutic effect determines which FDA center (CDER, CDRH, or CBER) has lead jurisdiction. Manufacturers can request formal clarification through a Request for Designation (RFD).
Assistant Manager – Projects & Process Engineering | 14 Years of Experience
Medical device manufacturing professional specializing in manufacturing plant feasibility, facility and cleanroom planning, process development, machinery selection, and equipment qualification (DQ, IQ, OQ, PQ). His expertise includes project cost estimation, procurement planning, and process optimization in alignment with ISO 13485:2016.


